**Euterpe oleracea** Extract (Açaí) Is a Promising Novel Pharmacological Therapeutic Treatment for Experimental Endometriosis

Daniel Escorsim Machado¹, Karina Cristina Rodrigues-Baptista¹,², Jessica Alessandra-Perini¹,², Roberto Soares de Moura³, Thiago Alves dos Santos¹,⁴, Kariny Gomes Pereira¹, Yasmin Marinho da Silva¹, Pergentino José Cunha Souza⁵, Luiz Eurico Nasciutti⁶, Jamila Alessandra Perini¹,²*

¹ Unidade de Farmácia, Centro Universitário Estadual da Zona Oeste, Rio de Janeiro, RJ, Brasil, ² Programa de Pós-Graduação em Saúde Pública e Meio Ambiente, Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brasil, ³ Departamento de Farmacologia e Psicobiologia, Universidade Estadual do Rio de Janeiro, Rio de Janeiro, RJ, Brasil, ⁴ Programa de Pós-Graduação em Biotecnologia e Engenharia Biológica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil, ⁵ Departamento de Farmácia, Universidade Federal do Pará, Belém, PA, Brasil, ⁶ Instituto de Ciências Biológicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil

* jamilaperini@yahoo.com.br

**Abstract**

This study investigated the therapeutic potential of *Euterpe oleracea* extract (açaí) on the growth and survival of endometriotic lesions using an experimental model. Twenty female Sprague-Dawley rats were randomized into two groups after the implantation and establishment of autologous endometrium onto the peritoneum abdominal wall and treated with 200 mg/kg hydroalcoholic solution extract from açaí stone or vehicle via gastric tube for 30 consecutive days. Body weight, lesion surface areas, histological and immunohistochemistry analyses of vascular endothelial growth factor (VEGF), VEGF receptor-2 (VEGFR-2), metalloproteinase-9 (MMP-9), cyclooxygenase-2 (COX-2) and F4-80 were performed. Levels of VEGF, VEGFR-2, MMP-9 and COX-2 mRNA were measured. Flow cytometry of F4-80 was performed, and ELISA immunoassays measured prostaglandin E₂ (PGE₂), VEGF and nitric oxide (NO) and concentrations. Macrophage cell line J774.G8 was treated with 10, 20, and 40 μg/mL of açaí for 24, 48 and 72 h, and cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Açaí treatment significantly decreased the implant size, and histological examination indicated atrophy and regression. A reduction in immunostaining and mRNA expression of VEGF, MMP-9 and COX-2 was observed, and F4-80 was lower in the treated group than the control group. The treated group also exhibited lower concentrations of PGE₂, VEGF and NO compared to the control group. Macrophages cells treated with 20 and 40 μg/mL of açaí reduced cell viability in about 50% after 24, 48 and 72 h. Our results suggest that açaí effectively suppressed the establishment and growth of endometriotic lesions, and this agent is a promising novel pharmacological therapeutic treatment for endometriosis.
Introduction

Endometriosis is defined as the presence of functional endometrium outside the uterine cavity that consists of proliferating functional endometrial glands and stroma [1]. It is an inflammatory disease associated with chronic pelvic pain and infertility, and it results in a markedly reduced quality of life [2]. The prevalence of the disease is in 5–10% of women of reproductive age [3].

The exact pathogenic mechanisms of endometriosis are not known, but several studies demonstrated that the development of a new vascular supply was essential for the establishment and growth of endometriotic lesions [4–6]. Various lines of evidence indicate that growth factors, including vascular endothelial growth factor (VEGF), cytokines and prostaglandins promote the development of endometriosis [7–9]. Notably, endometriotic lesions exhibit increased cyclooxygenase-2 (COX-2) expression compared to eutopic endometrium [10]. COX-2 and VEGF studies are associated with endometriosis and reinforce the hypothesis that the angiogenesis process and inflammation are crucial to the pathophysiology of this disease [8,11,12].

The current treatment for endometriosis is medical and/or surgical. Hormone therapy is the commonly used medical treatment, and it involves oral contraceptives, progestogens and gonadotropin-releasing hormone agonists, which induce a hypoestrogenic state [13]. However, these therapies can only be prescribed for a short time because of serious adverse effects, such as pseudomenopause, massive hemorrhage and bone density loss. The disease recurs within 3–5 years in 30–50% of women after surgical removal of endometriosis lesions [14]. Therefore, the search for additional strategies to effectively treat endometriosis is fundamental.

Euterpe oleracea Mart. (Arecaceae), popularly known as “açai”, is an economically important plant that is found widely in the Amazon region of Brazil. Chemical studies demonstrated that açai exhibits a diverse composition of hydroxybenzoic acids, antioxidant polyphenolics, flavan-3-ols, and anthocyanins, predominantly cyanidin 3-O-rutinoside and cyanidin 3-O-glucuronide [15–19]. Açai exhibits antioxidant, antinociceptive, anti-inflammatory and anticancer activities because of its high level of phytochemicals [20–26]. Açai exhibits exceptional activity against superoxides, inhibits reactive oxygen species (ROS) formation and may inhibit COX-2 [27]. A significant antinociceptive effect of açai was observed in a spinal nerve ligation model in rats, which suggests the possible development of a new analgesic drug [26]. Recently, Marques et al. conducted cytogenetic tests with three doses of açai in rat cells, and showed that açai had no significant genotoxic effects in the analyzed cells [28].

Endometriosis is an inflammatory disease and açai extract may be an effective treatment strategy. The present study investigated the pharmacological effects of açai on the establishment and growth of endometriotic lesions using an experimental model. We used several assays to investigate anti-inflammatory functions, including an activated macrophage study and nitric oxide (NO) assay. We also investigated whether açai modulated the angiogenesis process to better understand the mechanisms of action of the extract in the development of endometriosis.

Materials and Methods

Preparation of açai extract

Açai fruits were obtained from the Amazon Bay (Belém do Pará, Pará, Brazil), excicata number 29052 Museu Goeldi–Belém do Pará, and these study has been authorized by Conselho Nacional de Desenvolvimento Científico e Tecnológico—CNPq (Authorization: 010564/2015-2). We used in our study the hydroalcoholic solution extracted from açai stones, as previously
described [22,23,26]. Briefly, 200 g of açai stone were boiled in 400 ml of distilled water for 10 min with mixed for 2 min. The decoction was cooled to room temperature and extracted by addition of 400 ml of ethanol with shaking for 2 h. The hydroalcoholic extract was stored (4°C) for 10 days and filtered through Whatman filter paper. Ethanol was evaporated under low pressure at 55°C. The extract was lyophilized (Fisatom Equipamentos Científicos Ltda São Paulo) at temperatures from -30 to -40°C and under a vacuum of 200 mmHg, and frozen at -20°C.

Experimental animal model

Animals were treated in accordance with protocols approved by the State University of West Zone (UEZO) Institutional Animal Care and Use Committee (CEUA), protocol code CEUA-UEZO-002/2013, and all experiments were conducted in accordance with the ethical guidelines from the CEUA and the NIH Guidelines for the Care and Use of Laboratory Animals (http://oacu.od.nih.gov/regs/index.htm, 8th Edition; 2011).

Twenty female Sprague-Dawley rats (250–300 g) were used after reaching maturity at 8 weeks of age and were housed in polyethylene cages in the Bioterium of UEZO, and were kept at a constant temperature (25°C) under a 12-h light/dark cycle with free access to food and water.

With use of the method described by Vernon and Wilson [29], the animals were anesthetized with intramuscular injection of ketamine and xylazine. The abdomen was opened through a 3-cm midline incision to expose the uterus. One uterine horn was removed and the segment was placed in phosphate-buffered saline at 37°C and split longitudinally, 5×5mm pieces were sectioned and anchored with the endometrium side onto the peritoneum of the ventral abdominal wall by nonadsorbable polypropylene sutures (6–0 Prolene, Ethicon, Piscataway, NJ). Then, the abdomen was closed and the animals were allowed to recover from anesthesia.

Animal Treatment

Two weeks after the initial implant, ventral midline laparotomy was performed to determine the attachment and viability of endometrial explants. The animals were divided randomly into two groups of each ten animals: açai group was treated with daily 200 mg/kg body weight, dissolved in saline, by gastric tube for 30 consecutive days, and control group received saline as vehicle by gastric tube for 30 consecutive days. Body weight was measured every three day. After treatment, the rats were euthanized by anesthesia overdose, the peritoneal fluid was collected to flow cytometry, ELISA immunoassay and NO dosage, and the surface areas of the explant (length x width) were evaluated using ImageJ software (National Institutes of Health, Bethesda, MN). Each sample was dissected and immediately divided into one piece that was fixed in 10% buffered formalin and paraffin embedded for histologic and immunohistochemical studies, and another piece that was frozen in liquid nitrogen for RNA extraction.

Histology and Immunohistochemistry

Formalinfixed tissues were paraffin-embedded and cut into 4-micrometers-thick sections. Part of the sections were stained with Harris hematoxylin and eosin (HE), and examined microscopically at 200× magnification for the presence of histological hallmarks of endometriosis, such as endometrial glands and stroma. The other paraffin-embedded tissue sections were placed on silane-treated slides, and maintained at room temperature, as previously described [30]. Sections were incubated with the following antibodies: monoclonal antibody against VEGF SC-57496 (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:100 dilution,
monoclonal antibody against Flk-1 SC-6251 (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:100 dilution, polyclonal antibody against metalloproteinase-9 (MMP-9) SC-6840 (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:200 dilution, polyclonal antibody against COX-2 SC-1747 (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:100 dilution, and monoclonal antibody against F4-80 macrophage antigen SC-26642 (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:200 dilution. Incubations were carried out overnight and then revealed using LSAB2 Kit HRP, rat (Dako-Cytomation, Carpinteria, CA) with diaminobenzidine (3,3’-diaminobenzidine tablets; Sigma, St. Louis, MO) as the chromogen and counterstained with hematoxylin. For each case, negative control slides consisted of sections incubated with antibody vehicle or no immune rabbit or mouse serum.

Morphometric analysis

All tissues were examined by two blinded observers using a 400× magnification on light microscope (Nikon, Tokyo, Japan) connected to a digital camera (Coolpix 990; Nikon). Ten fields of an immunostained section (VEGF, VEGFR-2, MMP-9, COX-2 and F4-80) were chosen at random and captured from each specimen. Quantification was assessed on captured high-quality images (2048 × 1536 pixels buffer) using the Image Pro Plus 4.5.1 (Media Cybernetics, Silver Spring, MD). Data were stored in Adobe Photoshop, version 3.0, to enable uneven illumination and background color to be corrected. Histologic scores (H) for VEGF, VEGFR-2, MMP-9, COX-2 and F4-80 were calculated using the formula H = ΣPi, where I is the intensity ranging from 0 (negative cells) to 3 (deeply staining cells) and P is the percentage of staining cells for each given i, with P values of 1, 2, 3, 4, and 5 indicating <15%, 15–50%, 50–85%, >85%, and 100% positive-staining cells, respectively. The staining result was expressed as mean ± standard deviations.

TaqMan real-time reverse transcription-polymerase chain reaction

The m-RNA levels were quantified by TaqMan real-time polymerase chain reaction. RNA from endometriosis samples was isolated using the Trizol® reagent according to the manufacturer’s instructions, and quantified by the Nanodrop® spectrophotometer. Two micrograms of total RNA was used as a template for cDNA synthesis, using the SuperScript II® reverse transcriptase kit (Invitrogen®). TaqMan Universal PCR Master Mix (Applied Biosystems®) and a validated TaqMan assay was purchased from Applied Biosystems, and were used to quantify mouse VEGF (Mm01281449_m1), kinase insert domain receptor (KDR), gene which encodes VEGFR-2 (Mm01222421_m1), MMP-9 (Mm004422991_m1) and PTGS, gene which encodes COX-2 (Mm00478374_m1) expression levels, with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Mm99999915_g1) as an endogenous control. Triplicate TaqMan PCR assays for each gene target were performed in cDNA samples. Real-time reactions were conducted in a 7500 Real-Time thermocycler (Applied Biosystems®). The relative quantification of the target genes was performed using the Delta-Delta Ct method.

ELISA Immunoassay

Peritoneal fluid was collected by rinsing the abdominal cavity with 10 mL of PBS and immediately centrifuged at 1500 rpm during 10 min. Supernatants were stored at -70°C until assayed for VEGF and PGE2 by use of an enzyme immunoassay kit (Boster Biological Technology, Pleasanton, CA and Cayman Chemical, Ann Arbor, MI), according to manufacturer’s instructions. The concentrations were calculated from standard curves and all samples were assessed in triplicate. The VEGF and PGE2 measurement were performed by an automatic plate reader.
Flow cytometry

Peritoneal fluid was obtained ex vivo from rat after the treatments by washing twice with PBS, pH 7.2 containing 3% Fetal Bovine Serum (FBS) for flow cytometry analysis. For the control group, the same procedure was conducted. The cells were incubated with Fc blocking (clone 2.4G2) for 10 min. Before, the cells were incubated with monoclonal antibody FITC anti-F4/80 (BD Biosciences, USA). Samples were analyzed on a flow cytometer (FACSCalibur, BD Biosciences, USA), 10,000 events were counted for each animal sample and the data was analyzed using CellQuest (BD Biosciences, USA) and WinMDI 2.9 software packages.

Nitric oxide analysis

The production of NO was performed as described by Green et al. [31]. Supernatants were mixed in a ratio of 1:1 with the Griess reagent (1:1 volume 1% sulfanilamide in 5% phosphoric acid in deionized water with an equal volume of 0.1% N-[1-naphthyl]–ethylenediamine in deionized water). After 10 minutes, the mixture was read in an ELISA reader (540 nm) and quantification of NO production was based on a sodium nitrite standard curve.

Cell Culture and viability assay

The mouse macrophage cell line J774.G8 were grown in plastic bottles in a RPMI 1640 medium (Sigma Chemical Company, St Louis, MO) supplemented with 10% fetal bovine serum (GIBCO-Life Technologies, Rockville, MD), penicillin (100 U/mL), streptomycin (100 µg/mL), glutamine (2 mM) and HEPES (15 mM; Biochrom AG) at 37˚C in a humidified atmosphere of 5% CO₂ (S1 Fig).

When cultures formed a confluent, monolayer cells were scrapped, centrifuged and put to adhere in 96 wells plate with RPMI at a density of 2 × 10⁴ cell/ml. The cultured cells were treated with 10, 20, and 40 µg/ml of the Acai extracts for 24, 48 and 72 h. The supernatant was removed, and 10 µl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in RPMI medium was added to each well. Cells were incubated in a CO₂ chamber for 3 h with protection from light. After the medium were aspirated, 100 µl of dimethyl sulfoxide (DMSO) was added to the cells to dissolve the formazan. The absorbance at 538 nm was measured with a Spectra Max 190 spectrophotometer (Molecular Devices, Sunnyvale, CA, EUA).

Statistical analysis

Data are expressed as mean ± standard deviations (SD). Statistical comparisons between treated group and control were performed with Student t-test. For VEGF, VEGFR-2, MMP-9, COX-2 and F4-80 morphometric analysis, statistical calculations were carried out with use of the Stat-Xact-5 software program (CYTEL Software Corporation, Cambridge, MA). The relative quantification of the target genes was carried out using Delta-Delta Ct method. Cell culture and viability assay experiments were performed in triplicate (n = 3) and the data were expressed as mean ± SD. The Student-Newman-Keuls test was used to assess the presence of statistical differences between the groups when a statistically significant association was described by ANOVA. The level of significance for significant difference between groups was set at P <0.05 in all analyses.
Results

Açaí Suppresses Endometriosis Growth

The endometrial explants formed viable cystic and well-vascularized lesions after 15 days in all 20 animals (Fig 1A). The histopathological results revealed typical endometrial components, such as glands and stroma, which confirmed the viability of the lesions (Fig 1C). The maintenance and growth of the lesions were suppressed in the treated animals group, and an important decrease in implant size was observed (Fig 1B). The histological analyses revealed atrophy and regression of the lesion areas (Fig 1D). Measurements of the lesion area demonstrated a statistically significant difference between the groups (Fig 1E). There was no significant difference in weight over time between the treated açaí group and the control group (data not shown).

Açaí Inhibits Angiogenesis in Experimental Endometriosis

The angiogenesis process was investigated using mRNA expression, immunostaining and ELISA immunoassays based on MMP-9, VEGF and its receptor VEGFR-2 (S1 Table).
Quantitative real-time PCR demonstrated suppression of the levels of VEGF (Fig 2A) and MMP-9 (Fig 2D) mRNA transcripts, and ELISA revealed a decrease in VEGF concentration (Fig 2B) in the endometriotic lesions treated compared to the control group. However, KDR mRNA transcripts were not different among the two groups (Fig 2C). VEGF, VEGFR-2 and MMP-9 immunoreactivity was detected in the lesions, predominantly in the stroma, around the glands, and in the cytoplasm of endothelial cells in non-treated endometriosis. The distribution of these three angiogenic markers decreased in endometriosis animals treated with açai (Fig 3D, 3E and 3F) compared to the control group (Fig 3A, 3B and 3C). Histomorphometry evaluations of VEGF, VEGFR-2 and MMP-9 confirmed the observation of significant decreases ($P = .0001$) in these markers in endometriosis animals treated with açai (2.5 ± 0.9, 2.8 ±0.6 and 4.2 ± 0.8, respectively) compared to the control group (22.1 ± 1.1, 25.4 ± 2.5 and 27.5 ± 2.4, respectively).
Anti-inflammatory effect of açai on endometriotic lesions

The inflammatory profile of endometriotic lesions was analyzed using COX-2 mRNA expression, COX-2 immunostaining, and an ELISA immunoassay of prostaglandin 2 (PGE$_2$) (Table S2). The level of COX-2 mRNA transcripts (Fig 4A) and the intensity of the COX-2 reaction (Fig 4C) were reduced in endometriotic lesions treated with açai compared to the control group (Fig 4B). Histomorphometry evaluation of COX-2 was significantly smaller ($P = .0001$) in endometriosis animals treated with açai (5.9 ± 0.5) compared to the control group (30.8 ± 1.7). PGE$_2$ (Fig 4D) and NO (Fig 4E) concentrations were significantly higher in the control group compared to the açai group, which demonstrated the anti-inflammatory potential of the extract.

Açai decreased levels of macrophages

We analyzed the presence of F4/80-positive cells in the endometriotic lesions of both groups because of the role of macrophages in angiogenesis and inflammation. We identified a decrease in the number of macrophage-positive cells in treated endometriotic lesions (Fig 5B) compared to the control group (Fig 5A). We analyzed the presence of these cells in endometriotic tissue using immunostaining of a macrophage activation marker to confirm these observations. We observed an important decrease in the number of positive cells in the stroma compartment in the treated group (Fig 5D) compared to the control group (Fig 5C). The histological scores of F4-80 immunostaining (Table S3) confirmed these results (control, 49.3 ± 2.1 versus açai 15.3 ± 1.0, $P = .0001$). We also performed the viability assay using macrophage cell...
line J774.G8 treated with 10, 20 and 40 μg/ml of açai after 24, 48 and 72 h, and observed the significantly decreased the viability of macrophages cells in all açai-treated, except treatment with 10 μg/ml for 24 h (Fig 5D). Macrophages cells treated with 20 and 40 μg/ml of açai reduced cell viability in about 50% after all times, reinforcing the hypothesis that the açai acts directly in the macrophage decrease. In addition, we made hematological analyses and observed a marked lymphocytosis in control animals compared to the açai group (S3 Table). A recovery of leukocyte numbers to normal parameters was observed in the açai group compared to the group of animals without endometriosis (data not shown).

Discussion

Endometriosis frequently produces serious effects on professional, social and marital life because it is associated with infertility and severe and incapacitating painful symptoms, including chronic pelvic pain, dysmenorrhea and dyspareunia [3,32]. Therefore, pharmacological treatments for endometriosis maintain a hypoestrogenic environment and relieve pelvic pain, but the side effects of these therapies limit their long-term use. Natural therapies were used recently for the treatment of various inflammatory diseases, and these therapies may be an effective treatment strategy for endometriosis [33,34].

Several studies demonstrated that açai possesses high levels of phytochemicals with antioxidant, antinociceptive, anti-inflammatory, hypocholesterolemic, and anticancer activities
To our knowledge, this report is the first study to evaluate the anti-inflammatory and antiangiogenic effects of açai in endometriotic implants. Notably, our study used the hydro-alcoholic extracted from açai stones because this extract was previously described to be more active than the pulp extract [25,37].

An important decrease in the implant size was observed in the animals treated with açai, and the histopathological findings revealed marked atrophy and lesion regression. Other phytotherapies also suppressed endometriosis in a murine model. Ergenoglu et al. used the natural polyphenol resveratrol and demonstrated a significant reduction in implant size and considerable histological changes in endometrial foci at the end of the treatment period [38]. Another study examined the effects of a plant polyphenol extracted from the traditional Chinese medicine turmeric, curcumin, on endometriosis. Curcumin treatment decreased the ectopic endometrial glands and narrowed the lumen [39]. These studies support the potential application of phytotherapies as endometriosis treatments.

Angiogenesis is pivotal in the development of endometriosis [40,41], and anti-angiogenic agents from different substance groups are discussed as possible candidates for a new therapeutic approach [42–44]. Açai treated animals in our study exhibited reduced VEGF expression, which is the most prominent pro-angiogenic factor in endometriosis. Similar results of reduced VEGF expression were reported in endometriosis models treated with a prodrug of green tea and epigallocatechin-3-gallate [45–48]. We also demonstrated that the açai extract decreased VEGFR-2 distribution. These results are important because the binding of VEGF to VEGFR-2 enhances endothelial cell migration, proliferation and the release of various proteolytic enzymes [49].

Endometriosis is considered a benign disease, but it often presents characteristics of malignancy [40,50]. Women with endometriosis also exhibit an increased risk of cancer, especially ovarian cancer [50,51], which primarily occurs because both conditions require angiogenesis for maintenance and growth [52]. Some studies demonstrated an anti-tumorigenic activity of
açaí in HL-60 leukemia cells and attenuation of colon carcinogenesis in rats [53,54]. Silva et al. demonstrated the anticancer activity of açaí in different malignant cell lines [25]. These authors concluded that the extract exhibited anti-tumorigenic potential in the human breast cancer MCF-7 cells and reduced viability and morphological alterations [25]. These results may be attributed to the rich content of polyphenols, anthocyanin and flavonoids in açaí because these substances possess anticancer activity [25,53,54].

The invasive properties of endometriotic tissue are also related to the increased proteolytic activity and matrix remodeling. MMPs are essential for the degradation of the extracellular matrix, which contributes to endometriosis development [55,56]. Our study demonstrated that açaí played an important role in reducing the MMP-9 levels in endometriotic lesions. Similar studies using curcumin also demonstrated reduced MMP expression in the intrinsic apoptotic pathway [57,58]. Some authors reported that the increase in ROS was a major factor that increased MMP expression and activity [59,60]. Costa et al. demonstrated that açaí treatment downregulated MMPs in experimental hypertension, and suggested that this downregulation was the result of the antioxidant activity of açaí [35].

High levels of ROS are generated in endometriosis and induce cell damage and proliferation [61], which supports the important role of peritoneal macrophages in the secretion of pro-inflammatory/proangiogenic cytokines [56,62]. Our findings demonstrated that the presence of F4/80-positive macrophages and NO concentrations were higher in endometriotic lesions and statistically reduced in animals treated with açaí. These results support the role of flavonoids as the major polyphenols in açaí that exhibit large anti-oxidant activity [19]. Several studies described the pivotal importance of macrophages in pathophysiology of endometriosis [4,8,40,56] and we also demonstrated that açaí decreased the viability of macrophage line cells in vitro. Therefore, we suggest that açaí decrease of macrophages hence reduced ROS production and decreased the inflammatory and angiogenesis processes in endometriotic lesions.

We also investigated COX-2 and PGE$_2$ signals to elucidate the mechanisms of action of açaí in the endometriosis inflammatory process. Several authors previously described that PGE$_2$ induced VEGF and played an important role in the pathogenesis of endometriosis [56,63,64]. We observed reduced COX-2 and PGE$_2$ levels in animals treated with açaí, and this result was likely due to the high levels of anthocyanin in açaí [65]. Notably, the suppression of COX-2 expression by açaí may be a prerequisite for the effective control of endometriosis-related pain. This hypothesis is supported by the significant and potent antinociceptive effect of this extract in rodent models of acute and neuropathic pain [26].

Considerable evidence supports that a diet rich in polyphenols reduces the risk for many pathological conditions, including cardiovascular disease and cancer [66]. However, studies demonstrated an effect of fruits and vegetables on the risk of cancer, and many of the tested extracts have genotoxic potential [67,68]. Ribeiro et al. investigated the genotoxicity of açaí in bone marrow, peripheral blood, liver and kidney cells of mice using the micronuclei test and comet assay [69]. The results demonstrated that gavage administration of açaí was not genotoxic in mice, and its components may be exploited as a promoter of good health [69].

Finally, based on the results of this study and the previous ones, we propose a mechanism for the therapeutic effects of açaí for endometriosis (Fig 6). Macrophages play a key role in inflammatory and angiogenesis of endometriosis. We know that the macrophages are an important source of VEGF and it is essential in the establishment and growth of endometriotic lesion [4,40,70]. High concentration of VEGF returns to activated macrophage and bind with VEGFR-2. This signaling upregulating the MMP-9 transcription induces the extracellular matrix remodeling promoting the increase of the vascular density [71]. Moreover, the
activated macrophages synthesize high concentration of inducible nitric oxide synthase (iNOS) and generate NO [61]. On the other hand, this process increased the COX-2 and PGE2 levels to enhance the inflammatory process and angiogenesis [56,63,64]. Therefore, we propose that açaí decreases the number of activated macrophages resulting in the reduction of the target genes expression, suppressing the maintenance and growth of endometriotic lesion.

**Conclusions**

In conclusion, the results of this study demonstrated the antiangiogenic and anti-inflammatory potential of açaí, which produced morphological alterations in endometriotic lesions. Açaí may also modulate the progress of endometriosis and suppress the symptoms related to pain, which supports the possible development of a novel and effective drug. The actual
mechanisms of the beneficial effects of açai on endometriotic lesions are not completely understood, but we are optimistic that these effects will be reproducible in clinical tests, and we will continue our research of this extract.

Supporting Information

S1 Fig. Macrophage cell line. Morphology observations by phase-contrast microscopy of macrophage cell line J774.G8 in plastic bottles cultivated in a RPMI 1640 medium (A and B). (TIF)

S1 Table. Immunostaining and ELISA immunoassays based on MMP-9, VEGF and its receptor VEGFR-2. (XLS)

S2 Table. COX-2 immunostaining, and an ELISA immunoassay of PGE2. (XLS)

S3 Table. F4-80 immunostaining, and hematological analyses. (XLS)

Acknowledgments

This study was supported by the Brazilian agency Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro—FAPERJ, Brazil (E-26/010.002619/2014 and E-26/010.002644/2014).

Author Contributions

Conceptualization: DEM JAP RSM LEN.

Formal analysis: DEM JAP JA-P.

Funding acquisition: DEM JAP RSM LEN.

Investigation: DEM JAP RSM KCR-B JA-P TAS KGP YMS.

Methodology: DEM JAP RSM KCR-B JA-P.

Project administration: DEM JAP RSM LEN.

Resources: DEM JAP RSM TAS PJCS LEN.

Supervision: DEM JAP.

Validation: DEM JAP RSM LEN.

Visualization: DEM TAS LEN.

Writing – original draft: DEM JAP KCR-B JA-P.

Writing – review & editing: DEM JAP RSM KCR-B JA-P TAS LEN.

References

1. Galle PC. Clinical presentation and diagnosis of endometriosis. Obstet Gynecol Clin North Am. 1989; 16: 29–42. PMID: 2664621

2. Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I, et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod. 2012; 27: 1292–9. doi: 10.1093/humrep/des073 PMID: 22422778
3. Bulun SE. Endometriosis. N Engl J Med. 2009; 360: 268–79. doi: 10.1056/NEJMra0804690 PMID: 19144942

4. McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update. 2000; 6: 45–55. PMID: 10711829

5. Gilabert-Estelles J, Ramón LA, España F, Gilabert J, Vila V, Réganot E, et al. Expression of angiogenic factors in endometriosis: relationship to fibrinolytic and metalloproteinase systems. Hum Reprod. 2007; 22: 2120–7. doi: 10.1093/humrep/dem149 PMID: 17609243

6. Machado DE, Abrão MS, Berardo PT, Takinya CM, Nascimento LE. Vascular density and distribution of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) are significantly higher in patients with deeply infiltrating endometriosis affecting the rectum. Fertil Steril. 2008; 90: 148–55. doi: 10.1016/j.fertnstert.2007.05.076 PMID: 17765237

7. Wu MH, Shoji Y, Chuang PC, Tsai SJ. Endometriosis: disease pathophysiology and the role of prostanoids. Expert Rev Mol Med. 2007; 9: 1–20.

8. Laschke MW, Menger MD. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Update. 2007a; 13: 331–42.

9. Podgaec S, Abrao MS, Dias JA Jr, Rizzo LV, Oliveira RM, Barat E, et al. Expression of angiogenic factors in endometriosis: relations hip to fibrinolytic and metalloproteinase systems. Hum Reprod. 2007; 22: 1327–9. doi: 10.1093/humrep/dem149 PMID: 17234676

10. Ota H, Igarashi S, Sasaki M, Tanaka T. Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod. 2001; 16: 561–6. PMID: 11228229

11. Matsuzaki S, Canis M, Pouly JL, Wattiez A, Omura K, Mage G. Cyclooxygenase-2 expression in deep endometriosis and matched eutopic endometrium. Fertil Steril. 2004; 82: 1309–15. doi: 10.1016/j.fertnstert.2004.03.059 PMID: 15533352

12. Ruhland B, Agic A, Krampe J, Diedrich K, Hornung D. Innovations in conservative endometriosis treatment: an updated review. Minerva Ginecol. 2011; 63: 247–59. PMID: 21654610

13. Del Pozo-Insfran D, Brenes CH, Talcott ST. Phytochemical composition and pigment stability of Açaí (Euterpe oleracea Mart.). J Agric Food Chem. 2004; 52: 1539–45. doi: 10.1021/jf035189n PMID: 15030208

14. Lichtenthaler R, Rodrigues RB, Maia JG, Papagiannopoulos M, Fabricius H, Marx F. Total oxidant scavenging capacities of Euterpe oleracea Mart. (Açaí) fruits. Int J Food Sci Nutr. 2005; 56: 53–64. doi: 10.1080/0963748050082092 PMID: 16019315

15. Rodrigues RB, Lichtenthaler R, Zimmermann BF, Papagiannopoulos M, Fabricius H, Marx F, et al. Total oxidant scavenging capacity of Euterpe oleracea Mart. (açaí) seeds and identification of their polyphenolic compounds. J Agric Food Chem. 2006; 54: 4162–7. doi: 10.1021/jf058169p PMID: 16756342

16. Pacheco-Palencia LA, Duncan CE, Talcott ST. Phytochemical composition and thermal stability of two commercial açaí species, Euterpe oleracea and Euterpe precatoria. Food Chem. 2009; 115: 1199–205.

17. Kang J, Zhimin L, Wub T, Jensen GS, Schauss AG, Wua X. Anti-oxidant capacities of flavonoid compounds isolated from acai pulp (Euterpe oleracea Mart.). Food Chemistry. 2010; 122: 610–7.

18. Schauss AG, Wua X, Prior RL, Ou B, Patel D, Huang D, et al. Phytochemical and nutrient composition of the freeze-dried amazonian palm berry, Euterpe oleracea Mart. (açaí). J Agric Food Chem. 2006a; 54: 8598–603. doi: 10.1021/jf060976q PMID: 17061839

19. Stoner GD. Foodstuffs for preventing cancer: the preclinical and clinical development of berries. Cancer Prev Res. 2009; 2: 187–94.

20. de Moura RS, Pires KM, Santos Ferreira T, Lopes AA, Nesi RT, Resende AC, et al. Addition of açai (Euterpe oleracea) to cigarettes has a protective effect against emphysema in mice. Food Chem Toxicol. 2011; 49: 855–63. doi: 10.1016/j.fct.2010.12.007 PMID: 21147193

21. Poulos SM, Fisher DR, Larson J, Bielinski DF, Rimando AM, Carey AN, et al. Anthocyanin-rich açaí (Euterpe oleracea Mart.) fruit pulp fractions attenuate inflammatory stress signaling in mouse
brain BV-2 microglial cells. J Agric Food Chem. 2012; 60: 1084–93. doi: 10.1021/jf203989k PMID: 22224493

25. Silva DF, Vidal FC, Santos D, Costa MC, Morgado-Diaz JA, do Desterro MNBS, et al. Cytotoxic effects of Euterpe oleracea Mart. in malignant cell lines. BMC Complement Altern Med. 2014; 14: 175. doi: 10.1186/1472-6882-14-175 PMID: 24886139

26. Sudo RT, Neto ML, Monteiro CE, Amaral RV, Resende ÂC, Souza PJ, et al. Antinociceptive effects of hydroalcoholic extract from Euterpe oleracea Mart. (Açaí) in a rodent model of acute and neuropathic pain. BMC Complement Altern Med. 2015; 15: 208. doi: 10.1186/s12906-015-0724-2 PMID: 26134625

27. Schauss AG, Wu X, Prior RL, Ou B, Huang D, Owens J, et al. Antioxidant Capacity and Other Bioactivities of the Freeze-Dried Amazonian Palm Berry, Euterpe oleracea Mart. (Açaí). J Agric Food Chem. 2006b; 54: 8604–10.

28. Marques ES, Froder JG, Carvalho JCT, Rosa PCP, Perazzo FF, Maistro EL. Evaluation of the genotoxicity of Euterpe oleracea Mart. (Arecalesae) fruit oil (açaí), in mammalian cells in vivo. Food Chem Toxicol. 2016; 93: 13–19. doi: 10.1016/j.fct.2016.04.018 PMID: 27125964

29. Vernon MW, Wilson EA. Studies on the surgical induction of endometriosis in the rat. Fertil Steril. 1985; 44: 684–94. PMID: 2054348

30. Perini JA, Angeli-Gamba T, Alessandra-Perini J, Ferreira LC, Nasciutti LE, Machado DE. Topical application of Acheflan on rat skin injury accelerates wound healing: a histopathological, immunohistochemical and biochemical study. BMC Complement Altern Med. 2015; 30: 203.

31. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite and [15N] nitrite in biological fluids. Anal Biochem. 1982; 126: 131–8. PMID: 7181105

32. Perini JA, Cardoso JV, Berardo PT, Vianna-Jorge R, Nasciutti LE, Bellodi-Privato M, et al. Role of vascular endothelial growth factor polymorphisms (-2578C>A, -460 T>C, -1154G>A, +405G>C and +936C>T) in endometriosis: a case-control study with Brazilians. BMC Women’s Health. 2014; 14: 117. doi: 10.1186/1472-6874-14-117 PMID: 25255852

33. Kong S, Zhang YH, Liu CF, Tsui I, Guo Y, Ai BB, et al. The complementary and alternative medicine for endometriosis: a review of utilization and mechanisms. Evid Based Complement and Alternat Med. 2014; 2014: 146383.

34. Tekin YB, Guven S, Kirbas A, Kalkan Y, Tumkaya L, Guvenda g Guven ES. Is resveratrol a potential substitute for leuprolide acetate in experimental endometriosis? Eur J Obstet Gynecol Reprod Biol. 2015; 184: 1–6. doi: 10.1016/j.ejogrb.2014.10.041 PMID: 25462211

35. da Costa CA, de Oliveira PR, de Bern GF, de Cavalo CL, Nasciutti LE, Machado DE. Topical application of Acheflan on rat skin injury accelerates wound healing: a histopathological, immunohistochemical and biochemical study. BMC Complement Altern Med. 2015; 30: 203.

36. Perini JA, Cardoso JV, Berardo PT, Vianna-Jorge R, Nasciutti LE, Bellodi-Privato M, et al. Role of vascular endothelial growth factor polymorphisms (-2578C>A, -460 T>C, -1154G>A, +405G>C and +936C>T) in endometriosis: a case-control study with Brazilians. BMC Women’s Health. 2014; 14: 117. doi: 10.1186/1472-6874-14-117 PMID: 25255852

37. Marques ES, Froder JG, Carvalho JCT, Rosa PCP, Perazzo FF, Maistro EL. Evaluation of the genotoxicity of Euterpe oleracea Mart. (Arecalesae) fruit oil (açaí), in mammalian cells in vivo. Food Chem Toxicol. 2016; 93: 13–19. doi: 10.1016/j.fct.2016.04.018 PMID: 27125964

38. Perini JA, Angeli-Gamba T, Alessandra-Perini J, Ferreira LC, Nasciutti LE, Machado DE. Topical application of Acheflan on rat skin injury accelerates wound healing: a histopathological, immunohistochemical and biochemical study. BMC Complement Altern Med. 2015; 30: 203.

39. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite and [15N] nitrite in biological fluids. Anal Biochem. 1982; 126: 131–8. PMID: 7181105

40. Perini JA, Cardoso JV, Berardo PT, Vianna-Jorge R, Nasciutti LE, Bellodi-Privato M, et al. Role of vascular endothelial growth factor polymorphisms (-2578C>A, -460 T>C, -1154G>A, +405G>C and +936C>T) in endometriosis: a case-control study with Brazilians. BMC Women’s Health. 2014; 14: 117. doi: 10.1186/1472-6874-14-117 PMID: 25255852

41. Marques ES, Froder JG, Carvalho JCT, Rosa PCP, Perazzo FF, Maistro EL. Evaluation of the genotoxicity of Euterpe oleracea Mart. (Arecalesae) fruit oil (açaí), in mammalian cells in vivo. Food Chem Toxicol. 2016; 93: 13–19. doi: 10.1016/j.fct.2016.04.018 PMID: 27125964

42. Perini JA, Angeli-Gamba T, Alessandra-Perini J, Ferreira LC, Nasciutti LE, Machado DE. Topical application of Acheflan on rat skin injury accelerates wound healing: a histopathological, immunohistochemical and biochemical study. BMC Complement Altern Med. 2015; 30: 203.

43. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite and [15N] nitrite in biological fluids. Anal Biochem. 1982; 126: 131–8. PMID: 7181105

44. Perini JA, Cardoso JV, Berardo PT, Vianna-Jorge R, Nasciutti LE, Bellodi-Privato M, et al. Role of vascular endothelial growth factor polymorphisms (-2578C>A, -460 T>C, -1154G>A, +405G>C and +936C>T) in endometriosis: a case-control study with Brazilians. BMC Women’s Health. 2014; 14: 117. doi: 10.1186/1472-6874-14-117 PMID: 25255852

45. Marques ES, Froder JG, Carvalho JCT, Rosa PCP, Perazzo FF, Maistro EL. Evaluation of the genotoxicity of Euterpe oleracea Mart. (Arecalesae) fruit oil (açaí), in mammalian cells in vivo. Food Chem Toxicol. 2016; 93: 13–19. doi: 10.1016/j.fct.2016.04.018 PMID: 27125964
44. Becker CM, D’Amato RJ. Angiogenesis and antiangiogenesis therapy in endometriosis. Microvasc Res. 2007; 74: 121–30. doi: 10.1016/j.mvr.2007.04.008 PMID: 17574280

45. Laschke MW, Schwender C, Scheuer C, Vollmar B, Menger MD. Epigallocatechin-3-gallate inhibits estrogen-induced activation of endometrial cells in vitro and causes regression of endometriotic lesions in vivo. Hum Reprod. 2008; 23: 2308–18. doi: 10.1093/humrep/den245 PMID: 18603648

46. Xu H, Lui WT, Chu CY, Ng PS, Wang CC, Rogers MS. Anti-angiogenic effects of green tea catechin on an experimental endometriosis mouse model. Hum Reprod. 2009; 24: 608–18. doi: 10.1093/humrep/den417 PMID: 19088106

47. Xu H, Becker CM, Lui WT, Chu CY, Davis TN, Kung AL, et al. Green tea epigallocatechin-3-gallate inhibits angiogenesis and suppresses vascular endothelial growth factor C/vascular endothelial growth factor receptor 2 expression and signaling in experimental endometriosis in vivo. Fertil Steril. 2011; 96: 1721–9. doi: 10.1016/j.fertnstert.2011.07.008 PMID: 21821246

48. Wang CC, Xu H, Man GC, Zhang T, Chu KO, Chu CY, et al. Prodrug of green tea epigallocatechin-3-gallate (Pro-EGCG) as a potent anti-angiogenesis agent for endometriosis in mice. Angiogenesis. 2013; 16: 59–69. doi: 10.1007/s10456-012-9299-4 PMID: 22948799

49. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992; 13: 18–32. doi: 10.1210/edrv-13-1-18 PMID: 1372863

50. Kumar S, Munkarah A, Arabi H, Bandyopadhyay S, Semaan A, Hayek K, et al. Prognostic analysis of ovarian cancer associated with endometriosis. Am J Obstet Gynecol. 2011; 204: 63. doi: 10.1016/j.ajog.2010.08.017 PMID: 21074136

51. Melin A, Sparen P, Persson I, Bergqvist A. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum Reprod. 2006; 21: 1237–42. doi: 10.1093/humrep/dei462 PMID: 16431901

52. Becker CM, Beaudry P, Funakoshi T, Benny O, Zaslavsky A, Zurakowski D, et al. Circulating endothelial progenitor cells are up-regulated in a mouse model of endometriosis. Am J Pathol. 2011; 178: 1782–91. doi: 10.1016/j.ajpath.2010.12.037 PMID: 21435458

53. Del Pozo-Insfran D, Percival SS, Talcott ST. Açai (Euterpe oleracea) polyphenolics in their glycoside and aglycone forms induce apoptosis of HL-60 leukemia cells. J Agric Food Chem. 2006; 54: 1222–9. doi: 10.1021/jf052132n PMID: 16478240

54. Fragoso MF, Ribeiro DA, Barbisan LF. Açai (Euterpe oleracea) feeding attenuates dimethylhydrazine-induced rat colon carcinogenesis. Food Chem Toxicol. 2013; 58: 68–76. doi: 10.1016/j.fct.2013.04.011 PMID: 23597449

55. Di Carlo C, Bonifacio M, Tommaselli GA, Bifulco G, Guerra G, Nappi C. Metalloproteinases, vascular endothelial growth factor, and angiopoietin 1 and 2 in eutopic and ectopic endometrium. Fertil Steril. 2009; 91: 2315–23. doi: 10.1016/j.fertnstert.2008.03.079 PMID: 18644593

56. Machado DE, Berardo PT, Landgraf RG, Fernandes PD, Palmero C, Alves LM, et al. A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis with an antiangiogenic effect in a rat model. Fertil Steril. 2010; 93: 2674–9. doi: 10.1016/j.fertnstert.2009.11.037 PMID: 20056215

57. Swarnakar S, Paul S. Curcumin arrests endometriosis by downregulation of matrix metalloproteinase-9 activity. Indian J Biochem Biophys. 2009; 46: 59–65. PMID: 19374255

58. Jana S, Paul S, Swarnakar S. Curcumin as anti-endometriotic agent: implication of MMP-3 and intrinsic apoptotic pathway. Biochem Pharmacol. 2012; 83: 797–804. doi: 10.1016/j.bcp.2011.12.030 PMID: 22227273

59. Grote K, Flach I, Luchtefeld M, Akin E, Holland SM, Drexlter H, et al. Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive species. Circ Res. 2003; 92: e80–6. doi: 10.1161/01.RES.0000077044.60138.7C PMID: 12750313

60. Castro MM, Rizi J, Ceron CS, Bendhack LM, Gerlach RF, et al. Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic Biol Med. 2009; 46: 2988–307. doi: 10.1016/j.freeradbiomed.2009.02.011 PMID: 19248829

61. Jackson LW, Schisterman EF, Dey-Rao R, Browne R, Armstrong D. Oxidative stress and endometriosis. Hum Reprod. 2005; 20: 2014–20. doi: 10.1093/humrep/dei001 PMID: 15817589

62. Tosti C, Pinzauti S, Santulli P, Chapron C, Petraglia F. Pathogenetic Mechanisms of Deep Infiltrating Endometriosis. Reprod Sci. 2015; 22: 1053–9. doi: 10.1177/1933719115592713 PMID: 26169038

63. Laschke MW, Elitzsch A, Scheuer C, Vollmar B, Menger MD. Selective cyclooxygenase-2 inhibition induces regression of autologous endometrial grafts by downregulation of vascular endothelial growth factor-mediated angiogenesis and stimulation of caspase-3-dependent apoptosis. Fertil Steril. 2007b; 87: 163–71.
64. Olivares C, Bilotas M, Buquet R, Borghi M, Sueldo C, Tesone M, et al. Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis. Hum Reprod. 2008; 23: 2701–8. doi: 10.1093/humrep/den315 PMID: 18716040

65. Heinrich M, Dhanji T, Casselman I. Açai (Euterpe oleracea Mart.) A phytochemical and pharmacological assessment of the species health claims. Phytochemistry Letters. 2011; 4: 10–21.

66. Ghosh D, Scheepens A. Vascular action of polyphenols. Mol Nutr Food Res. 2009; 53: 322–31. doi: 10.1002/mnfr.200800182 PMID: 19051188

67. Fang X, Wei J, He X, An P, Wang H, Jiang L, et al. Landscape of dietary factors associated with risk of gastric cancer: A systematic review and dose-response meta-analysis of prospective cohort studies. Eur J Cancer. 2015; 51: 2820–32. doi: 10.1016/j.ejca.2015.09.010 PMID: 26589974

68. Zanini S, Marzotto M, Giovinazzo F, Bassi C, Bellavite P. Effects of dietary components on cancer of the digestive system. Crit Rev Food Sci Nutr. 2015; 55: 1870–85. doi: 10.1080/10408398.2012.732126 PMID: 24841279

69. Ribeiro JC, Antunes LM, Aissa AF, Darin JD, De Rosso VV, Mercadante AZ, et al. Evaluation of the genotoxic and antigenotoxic effects after acute and subacute treatments with açai pulp (Euterpe oleracea Mart.) on mice using the erythrocyte micronucleus test and the comet assay. Mutat Res. 2010; 695: 22–8. doi: 10.1016/j.mrgentox.2009.10.009 PMID: 19892033

70. Lin YJ, Lai MD, Lei HY, Wing LYC. Neutrophils and Macrophages Promote Angiogenesis in the Early Stage of Endometriosis in a Mouse Model. Endocrinology, 2006; 147(3):1278–1286. doi: 10.1210/en.2005-0790 PMID: 16306083

71. Jeon SH, Chae BC, Kim HA, Seo GY, Seo DW, Chun GT, et al. Mechanisms underlying TGF-1-induced expression of VEGF and Flk-1 in mouse macrophages and their implications for angiogenesis. J Leukoc Biol, 2007; 81(2):557–66. doi: 10.1189/jlb.0806517 PMID: 17053163